107 related articles for article (PubMed ID: 35584386)
1. Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Iede K; Yamada T; Koh M; Ueda M; Tsuda Y; Nakashima S; Ohta K; Tanida T; Matsuyama J; Ikenaga M; Tominaga S
Pancreas; 2022 Mar; 51(3):278-281. PubMed ID: 35584386
[TBL] [Abstract][Full Text] [Related]
2. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer.
Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1289. PubMed ID: 32969199
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer.
Iede K; Yamada T; Ishida T; Tsuda Y; Nakashima S; Tanida T; Matsuyama J; Nakata K; Tominaga S
Pancreas; 2024 Jan; 53(1):e22-e26. PubMed ID: 38157455
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1215. PubMed ID: 32672000
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
10. Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Ishizaki A; Okuwaki K; Kida M; Imaizumi H; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Watanabe M; Kurosu T; Ishizaki J; Kusano C
Intern Med; 2023 Oct; 62(19):2783-2793. PubMed ID: 36792197
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Pelzer U; Wislocka L; Jühling A; Striefler J; Klein F; Roemmler-Zehrer J; Sinn M; Denecke T; Bahra M; Riess H
Eur J Cancer; 2018 Sep; 100():85-93. PubMed ID: 30014884
[TBL] [Abstract][Full Text] [Related]
12. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Zhang H; Kellett C; Lambert P; Kim CA
Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
[TBL] [Abstract][Full Text] [Related]
14. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Emori T; Itonaga M; Ashida R; Tamura T; Kawaji Y; Hatamaru K; Yamashita Y; Shimokawa T; Koike M; Sonomura T; Kawai M; Kitano M
Pancreatology; 2022 Mar; 22(2):277-285. PubMed ID: 35033425
[TBL] [Abstract][Full Text] [Related]
15. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
16. Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Relias V; Maloney A; Smith MH; Saif MW
Cancer Chemother Pharmacol; 2017 Aug; 80(2):371-375. PubMed ID: 28664225
[TBL] [Abstract][Full Text] [Related]
17. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
20.
Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]